Assembly Biosciences, Inc.
NASDAQ: ASMB0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jason A. Okazaki
- Employees
- 73
- Headquarters
- South San Francisco, United States
- IPO year
- 2010
- Market cap
- $407.2M
- Website
- https://www.assemblybio.com
Loading ASMB…
Loading profile data…Frequently asked questions about ASMB
What does Assembly Biosciences, Inc. (ASMB) do?
Assembly Biosciences, Inc. is a biotechnology firm in the clinical development phase, dedicated to identifying and advancing innovative therapeutic solutions for hepatitis B virus (HBV) infections within the United States. Its primary drug candidate, Vebicorvir, has successfully concluded Phase 2 clinical trials for individuals with chronic HBV....
Where does ASMB trade?
Assembly Biosciences, Inc. (ASMB) trades on the NASDAQ Global Select.
What sector is ASMB in?
Assembly Biosciences, Inc. (ASMB) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Assembly Biosciences, Inc.?
Jason A. Okazaki is the chief executive officer of Assembly Biosciences, Inc. (ASMB).
Where is Assembly Biosciences, Inc. headquartered?
Assembly Biosciences, Inc. is headquartered in United States.
Does ASMB pay a dividend?
Assembly Biosciences, Inc. (ASMB) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ASMB go public?
Assembly Biosciences, Inc. (ASMB) completed its initial public offering in 2010.